Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00107
|
|||||
| Drug Name |
Levothyroxine
|
|||||
| Synonyms |
(-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5"-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine;O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; DL-Thyroxin; Eltroxin; Eltroxin (TN); Euthyrox; Euthyrox (TN); Eutirox (TN); Forthyron; Forthyron (TN); L-3,5,3',5'-Tetraiodothyronine; L-T4; L-Thryoxin; L-Thyroxin; L-thyroxine; L-thyroxine (TN); LT00440967; Laevothyroxinum; Laevothyroxinum (acid); Laevoxin; Levaxin (TN); Levo-T; Levolet; Levothroid; Levothroid (*Sodiumsalt*); Levothyrox; Levothyroxin; Levothyroxine (BAN); Levothyroxine Sodium (L-thyroxine); Levothyroxine sodium; Levothyroxinum (acid); Levoxyl; Levoxyl (TN); O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; Oroxine; Synthroid; Synthroid (*Sodium salt*); Synthroid (TN); Synthroid sodium; T-3850; T4 (Hormone); T4 levothyroxine; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyrax (TN); Thyreoideum; Thyrox (TN); Thyroxevan; Thyroxin; Thyroxinal; Thyroxine (VAN); Thyroxine (l); Thyroxine [BAN]; Thyroxine iodine; Thyroxine, L-(8CI)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hypothyroidism [ICD11: 5A00.2] | Approved | [1] | |||
| Therapeutic Class |
Antithyroid Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H11I4NO4
|
|||||
| Canonical SMILES |
C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N
|
|||||
| InChI |
InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1/i16-2
|
|||||
| InChIKey |
XUIIKFGFIJCVMT-SUXPHOQTSA-N
|
|||||
| CAS Number |
CAS 51-48-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 774.87 | Topological Polar Surface Area | 92.8 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.4
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
ChEBI:18332
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1C1 | Transporter Info | Organic anion transporting polypeptide 1C1 | Substrate | [4] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OATP1A2 | Transporter Info | Km = 8 microM | Oocytes-OATP1A2 | [2] | |
| OATP1B1 | Transporter Info | Km = 3 microM | Oocytes-OATP1B1 | [3] | ||
| OATP1C1 | Transporter Info | Km = 0.0904 microM | Chinese hamster ovary (CHO) cells-OATP1C1 | [4] | ||
| References | ||||||
| 1 | Levothyroxine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12. | |||||
| 3 | Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63. | |||||
| 4 | Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.